Halozyme Therapeutics, Inc.
US ˙ NasdaqGS ˙ US40637H1095

SecurityHALO / Halozyme Therapeutics, Inc.
InstitutionRYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity
Latest Disclosed Ownership2,035 shares
Latest Disclosed Value $ 105,860
RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity reports 3.88% increase in ownership of HALO / Halozyme Therapeutics, Inc.

On August 27, 2025 - RYDEX VARIABLE TRUST - Biotechnology Fund Variable Annuity filed a NPORT-P form disclosing ownership of 2,035 shares of Halozyme Therapeutics, Inc. (US:HALO) valued at $105,861 USD as of June 30, 2025. The entity filed a previous NPORT-P on May 29, 2025 disclosing 1,959 shares of Halozyme Therapeutics, Inc.. This represents a change in shares of 3.88% during the quarter. The current value of the position is $145,706 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2025-08-27 2025-06-30 NP Halozyme Therapeutics EC US40637H1095 2,035 76 3.88 106 -16.00 1.1765
2025-05-29 2025-03-31 NP Halozyme Therapeutics EC US40637H1095 1,959 -344 -14.94 125 13.64 1.3279
2025-03-03 2024-12-31 NP Halozyme Therapeutics EC US40637H1095 2,303 2 0.09 110 -16.03 1.1038
2024-11-29 2024-09-30 NP Halozyme Therapeutics EC US40637H1095 2,301 -313 -11.97 132 -3.68 1.1930
2024-08-29 2024-06-30 NP Halozyme Therapeutics EC US40637H1095 2,614 -660 -20.16 137 2.26 1.2478
2024-05-30 2024-03-31 NP Halozyme Therapeutics EC US40637H1095 3,274 70 2.18 133 12.71 1.1295
2024-02-29 2023-12-31 NP Halozyme Therapeutics EC US40637H1095 3,204 -499 -13.48 118 -16.31 0.9706
2023-11-29 2023-09-30 NP Halozyme Therapeutics EC US40637H1095 3,703 -341 -8.43 141 -2.76 1.2247
2023-08-28 2023-06-30 NP Halozyme Therapeutics EC US40637H1095 4,044 -68 -1.65 146 -7.64 1.1511
2023-05-30 2023-03-31 NP Halozyme Therapeutics EC US40637H1095 4,112 45 1.11 157 -32.03 1.1895
2023-02-28 2022-12-31 NP Halozyme Therapeutics EC US40637H1095 4,067 -361 -8.15 231 32.00 1.3995
2022-11-29 2022-09-30 NP Halozyme Therapeutics EC US40637H1095 4,428 281 6.78 175 -3.85 1.2218
2022-08-29 2022-06-30 NP Halozyme Therapeutics EC US40637H1095 4,147 -976 -19.05 182 -10.78 1.2518
2022-05-26 2022-03-31 NP Halozyme Therapeutics EC US40637H1095 5,123 -926 -15.31 204 -16.05 1.2072
2022-02-28 2021-12-31 NP Halozyme Therapeutics EC US40637H1095 6,049 769 14.56 243 13.55 1.0748
2021-11-29 2021-09-30 NP Halozyme Therapeutics EC US40637H1095 5,280 -183 -3.35 215 -13.71 0.9029
2021-08-27 2021-06-30 NP Halozyme Therapeutics EC US40637H1095 5,463 -47 -0.85 248 8.30 1.0390
2021-05-27 2021-03-31 NP Halozyme Therapeutics EC US40637H1095 5,510 -806 -12.76 230 -14.87 1.0336
2021-03-01 2020-12-31 NP Halozyme Therapeutics EC US40637H1095 6,316 6,316 270 1.0986
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.